Drug Search Results

Telaglenastat

Alternative Names: telaglenastat, cb-839
Latest Update: 2025-02-26
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: GLS Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Calithera Biosciences
Company Location: SOUTH SAN FRANCISCO CA 94080
Company CEO: Susan M. Molineaux
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Telaglenastat

Countries in Clinic: United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Cervical Cancer|Colorectal Cancer|Uterine Cancer

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
R01CA181745	P2	Not yet recruiting	Uterine Cancer\|Cervical Cancer	2031-08-07
VICC GI 1703	P2	Completed	Colorectal Cancer	2023-08-15

Recent News Events

Date	Type	Title
05/10/2024	PubMed	Glutamine Metabolism Heterogeneity in Glioblastoma Unveils an Innovative Combination Therapy Strategy.
05/02/2024	PubMed	Analysis of anti-tumor effect and mechanism of GLS1 inhibitor CB-839 in colorectal cancer using a stroma-abundant tumor model.
04/30/2024	PubMed	METTL3-mediated m6A methylation of SLC38A1 stimulates cervical cancer growth.
08/15/2022	News Article	Calithera Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights
07/13/2022	News Article	Calithera Biosciences Shares Progress in Sapanisertib and Mivavotinib Clinical Programs at Upcoming Lung Cancer and Lymphoma Conferences
11/05/2021	News Article	Calithera Biosciences Announces Decision to Discontinue KEAPSAKE Clinical Trial
10/18/2021	News Article	Calithera Expands Oncology Pipeline with Acquisition of Two Clinical-Stage Assets from Takeda Pharmaceuticals

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions